- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | 24/7 Market News and NeOnc Technology: NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum | 1 | GlobeNewswire (USA) | ||
| Di | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | NeOnc receives UAE approval for NEO100 glioma drug trials | 1 | Investing.com | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Di | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone | 144 | GlobeNewswire (Europe) | Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where... ► Artikel lesen | |
| Mo | WallStreet-PR: WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy | 316 | Newsfile | Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend years attempting to secure: international... ► Artikel lesen | |
| 16.06. | 24/7 Market News and NeOnc Technology: Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND | 1 | GlobeNewswire (USA) | ||
| 16.06. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development | 1 | GlobeNewswire (USA) | ||
| 15.06. | WallStreet-PR: WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates | 258 | Newsfile | Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology sector as the Company advances its neuro-oncology... ► Artikel lesen | |
| 12.06. | NeOnc Technologies secures $5M private placement via Series A preferred stock | 2 | Seeking Alpha | ||
| 12.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | 24/7 Market News and NeOnc Technology: The Next Great AI Revolution May Be Drug Delivery | 2 | GlobeNewswire (USA) | ||
| 19.05. | 24/7 Market News and NeOnc Technology: NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones | 1 | GlobeNewswire (USA) | ||
| 18.05. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | NeOnc Technologies Holdings GAAP EPS of -$0.38 | 2 | Seeking Alpha | ||
| 18.05. | NeOnc Technologies Holdings, Inc.: NeOnc Provides Business Update and Reports Q1 2026 Financial Results | 875 | GlobeNewswire (Europe) | CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs... ► Artikel lesen | |
| 07.05. | 24/7 Market News and NeOnc Technology: Biotech's Next Wave May Already be in Motion | 1 | GlobeNewswire (USA) | ||
| 24.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.04. | BTIG stuft NeOnc Technologies mit "Kaufen" ein - Hoffnungsträger bei ZNS-Tumoren | 12 | Investing.com Deutsch | ||
| 24.04. | BTIG initiates NeOnc Technologies stock with buy on CNS tumor drugs | 1 | Investing.com | ||
| 18.04. | New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings, Neonc Technologies Holdings, Medicus Pharma, YY Group Holding, and Vivos Therapeutics | 850 | ACCESS Newswire | The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| PALATIN TECHNOLOGIES | 11,440 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | -3,86 % | NurExone bringt Entwicklung, Finanzierung und US-Ausbau voran | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,390 | -4,37 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,892 | +1,53 % | RedHill Biopharma closes $6 million private placement | ||
| ONCO-INNOVATIONS | 0,460 | -2,23 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| NOVOCURE | 13,470 | 0,00 % | Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start... ► Artikel lesen | |
| PHARMING | 1,157 | +0,87 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,800 | +1,73 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| REVOLUTION MEDICINES | 160,00 | +0,03 % | Revolution Medicines, Inc.: Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic ... | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,870 | 0,00 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| PALISADE BIO | 1,895 | +0,26 % | Palisade Bio, Inc.: Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors | Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,955 | +0,75 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from... ► Artikel lesen | |
| OMEROS | 7,560 | -0,79 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen |
NEONC TECHNOLOGIES HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,22 % bei einem Aktienkurs von 4,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.